Nektar Therapeutics - Financial and Strategic Analysis Review

Summary

Nektar Therapeutics - Financial and Strategic Analysis Review

Nektar Therapeutics, a biopharmaceutical company engaged in the development of differentiated therapeutics with the PEGylation and pulmonary drug development technology platforms. The company has two lead products in development namely Oral NKTR-118 and NKTR-102. It is developing a strong pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. The company is headquartered in California, United States.

Global Markets Direct's Nektar Therapeutics - Financial and Strategic Analysis Review is an in-depth business, strategic and financial analysis of Nektar Therapeutics. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis of the company. This highlights its strengths and weaknesses and the opportunities and threats it faces going forward.

Scope

• Provides key company information for business intelligence needs.
• The company's strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered.
• The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted.
• The report contains critical company information - business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
• The report provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.
• Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Reasons to buy

• A quick "one-stop-shop" to understand the company.
• Enhance business/sales activities by understanding customers' businesses better.
• Get detailed information and financial and strategic analysis on companies operating in your industry.
• Identify prospective partners and suppliers - with key data on their businesses and locations.
• Capitalize on competitor's weaknesses and target the market opportunities available to them.
• Compare your company's financial trends with those of your peers / competitors.
• Scout for potential acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Contents

• Key Information
• Key Ratios
• Share Data
• Performance Chart
• List of Tables
• List of Figures
  • Key Facts
  • Business Description
  • Major Products and Services
  • Overview
  • History
  • SWOT Analysis Overview
  • Overview
  • Nektar Therapeutics - Strengths
  • Sturdy research and development activities
  • Robust Product Portfolio
  • Strong Liquidity Position
  • Nektar Therapeutics - Weaknesses
  • Termination of Pfizer-Exubera contract
  • Limited Geographic Presence
  • Nektar Therapeutics - Opportunities
  • Agreements
  • Changing Demographics
  • Medicare Part D
  • Nektar Therapeutics - Threats
  • Effect of Global Slowdown
  • Tightening of FDA's Regulatory Oversight
  • Increased Pricing Control
  • Key Competitors
  • Key Employees
  • Key Employee Biographies
  • Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Financial Ratios
  • Capital Market Ratios
  • Annual Ratios
  • Interim Ratios
  • Ratio Charts
• Appendix
  • Methodology
  • Ratio Definitions
  • About Global Markets Direct
  • Contact Us
  • Disclaimer
• List of Tables
  • Nektar Therapeutics, Key Facts
  • Nektar Therapeutics, Key Ratios
  • Nektar Therapeutics, Share Data
  • Nektar Therapeutics, Key Facts
  • Nektar Therapeutics, History
  • Nektar Therapeutics, Key Employees
  • Nektar Therapeutics, Key Employee Biographies
  • Nektar Therapeutics, Subsidiaries
  • Nektar Therapeutics, Ratios based on current share price
  • Nektar Therapeutics, Annual Ratios
  • Nektar Therapeutics, Interim Ratios
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
• List of Figures
  • Nektar Therapeutics, Performance Chart (2004 - 2008)
  • Nektar Therapeutics, Ratio Charts